These newly identified SNPs in ACMSD, BST1, and CD38 may serve as potential biomarkers for clinical differential diagnoses and as potential treatment targets for the modulation of NAD level in MDD patients carrying these SNPs. This evidence concerns the gene BST1 and major depressive disorder.